文献速递肝病

原发性胆汁性胆管炎中对熊去氧胆酸的充分应答与深度应答:在何种程度和条件下碱性磷酸酶正常与无并发症生存获益相关

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
PubMed 文献 · Hepatology · 2023-07-03

该回顾性队列纳入1047例按Paris-2标准对熊去氧胆酸(UDCA)充分应答的原发性胆汁性胆管炎(PBC)患者,评估碱性磷酸酶(ALP)正常与无并发症生存的关系。整体人群ALP正常与10年无并发症生存绝对获益相关(平均7.6个月,95%CI 2.7-12.6,P=0.003);在肝硬度≥10 kPa和/或年龄≤62岁亚组中,同时满足两条件者10年绝对获益达52.8个月(95%CI 45.7-59.9,P<0.001)。作者认为ALP持续在1.1-1.5×ULN的充分应答患者仍存在不良结局风险,应考虑进一步治疗。

要点

  • UDCA充分应答的PBC患者中,ALP正常与10年无并发症生存绝对获益平均7.6个月相关。
  • 肝硬度≥10 kPa和/或年龄≤62岁者,同时满足两条件时10年绝对获益52.8个月。
  • ALP持续1.1-1.5×ULN的充分应答患者仍存在不良结局风险,作者认为应考虑进一步治疗。

核心结论

  • UDCA充分应答的PBC患者中,ALP正常与10年无并发症生存绝对获益相关;ALP持续1.1-1.5×ULN者尤其合并晚期纤维化和/或足够年轻者仍存在不良结局风险,作者认为应考虑进一步治疗。

研究设计与样本

  • 回顾性队列研究,纳入1047例按Paris-2标准对UDCA充分应答的PBC患者,采用校正限制性平均生存时间(RMST)分析评估至肝脏相关并发症、肝移植或死亡的时间。

主要发现

  • 总体事件发生率为每1000人年17.0(95%CI 13.7-21.1),共计4763.2人年。
  • 整体人群中,血清ALP正常与10年无并发症生存绝对获益显著相关(平均7.6个月,95%CI 2.7-12.6,P=0.003)。
  • 整体人群中,GGT正常、ALT正常、AST正常或总胆红素<0.6×ULN与10年无并发症生存绝对获益无显著相关。
  • 亚组分析中,肝硬度≥10 kPa和/或年龄≤62岁者ALP正常的关联显著;同时满足两条件时10年绝对无并发症生存获益为52.8个月(95%CI 45.7-59.9,P<0.001)。

关键数值与推荐

  • Paris-2标准用于定义对UDCA的充分应答。
  • ALP持续高于1.5×ULN且UDCA治疗12个月后仍如此时推荐二线治疗。
  • ALP持续在1.1-1.5×ULN的充分应答患者仍存在不良结局风险。

临床怎么用

  • 作者认为,对UDCA充分应答但ALP持续在1.1-1.5×ULN的PBC患者,尤其合并晚期纤维化和/或足够年轻者,应考虑进一步治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated with better long-term outcome. However, second-line therapies are currently recommended only when ALP levels remain above 1.5 times the upper limit of normal (×ULN) after 12-month UDCA. We assessed whether, in patients considered good responders to UDCA, normal ALP levels were associated with significant survival gains. APPROACH AND RESULTS: We performed a retrospective cohort study of 1047 patients with PBC who attained an adequate response to UDCA according to Paris-2 criteria. Time to liver-related complications, liver transplantation, or death was assessed using adjusted restricted mean survival time (RMST) analysis. The overall incidence rate of events was 17.0 (95% CI: 13.7-21.1) per 1000 out of 4763.2 patient-years. On the whole population, normal serum ALP values (but not normal gamma-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), or aspartate aminotransferase (AST); or total bilirubin < 0.6 ×ULN) were associated with a significant absolute complication-free survival gain at 10 years (mean 7.6 months, 95% CI: 2.7 - 12.6 mo.; p = 0.003). In subgroup analysis, this association was significant in patients with a liver stiffness measurement ≥ 10 kPa and/or age ≤ 62 years, with a 10-year absolute complication-free survival gain of 52.8 months (95% CI: 45.7-59.9, p < 0.001) when these 2 conditions were met. CONCLUSIONS: PBC patients with an adequate response to UDCA and persistent ALP elevation between 1.1 and 1.5 ×ULN, particularly those with advanced fibrosis and/or who are sufficiently young, remain at risk of poor outcome. Further therapeutic efforts should be considered for these patients.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Corpechot C, Lemoinne S, Soret PA, et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatology. 2023. PMID: 37399238. doi:10.1097/HEP.0000000000000529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。